Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT03753555
PHASE4

The Effect of InTensive Statin in Ischemic Stroke With inTracranial Atherosclerotic Plaques

Sponsor: General Hospital of Shenyang Military Region

View on ClinicalTrials.gov

Summary

Intracranial atherosclerotic disease is the most common cause of ischemic stroke that is directly attributed to the progression or rupture of intracranial high-risk plaque in Asia. Many studies mainly from Euro-American population with a focus on extracranial carotid plaque have fully demonstrated the advantages of intensive statin therapy on stabilizing or reversing plaque burden, reversing plaque composition presenting that lipid-rich necrotic core (LRNC) is gradually replaced by fibrous tissue, and even reversing pattern of arterial remodeling to reduce the occurrence of cerebrovascular events. Yet, direct evidence of the effect of intensive statin therapy on intracranial atherosclerotic plaques is lacking and the effect of statin intensity and duration on intracranial plaque burden and composition is still unclear. High resolution magnetic resonance imaging (HRMRI) is a new and non-invasive technique that enable to assess the morphologic characteristics of vascular wall and plaque composition of intracranial artery. Based on above discussion, the investigators conduct this study to further determine the effect of intensive statin in ischemic stroke with intracranial atherosclerotic plaques.

Official title: The Effect of InTensive Statin in Ischemic Stroke With inTracranial Atherosclerotic Plaques: a Prospective, Random, Single-center Study Based on High Resolution Magnetic Resonance Imaging

Key Details

Gender

All

Age Range

18 Years - 80 Years

Study Type

INTERVENTIONAL

Enrollment

100

Start Date

2018-12-01

Completion Date

2026-11-30

Last Updated

2025-03-18

Healthy Volunteers

No

Interventions

DRUG

Atorvastatin Calcium

20mg Qd for 12 months

DRUG

Atorvastatin Calcium

40-80mg Qd for 6 months

DRUG

Probucol

0.5g Bid for 6 months

DRUG

PCSK9 inhibitor

Evolocumab 140mg subcutaneously injected, twice each month

Locations (1)

General Hospital of ShenYang Military Region

Shenyang, China